Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEAP-006: Pembrolizumab + platinum/pemetrexed chemotherapy with or without lenvatinib in first-line metastatic nonsquamous NSCLC
jRCT2080224588Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2019
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of pembrolizumab, lenvatinib, pemetrexed, carboplatin and cisplatin in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Merck & Co. Primary endpoints: Overall Survival (OS) and Progression-Free Survival (PFS). Started Mar 2019; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2080224588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224588.